大和：上调对药明生物(02269)目标价至42港元维持“买入”评级

14 1 月, 2026

One Min Read

10 Views

Last Update: 14 1 月, 2026

Written By

Other Articles

Previous

港股异动 | 中广核电力(01816)午后跌超4% 花旗称中国未见电力短缺广东省电价或低于预期

Next

花旗：予比亚迪(01211)“买入”评级目标价174港元

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept